CUMULATIVE INDEX 1999

Volume 17

January	ADVANCES IN MILITARY DERMATOLOGY, pages 1–244
April	HAIR RESTORATION AND LASER HAIR REMOVAL, pages 245–443
July	UPDATE ON DERMATOPATHOLOGY, pages 445–721
October	LIPOSUCTION, pages 723–915

Note: Page numbers of article titles are in **boldface** type

Abdomen, liposuction of, **823–834**, **835–848**
anatomy in, 835–837
body forms in, 837–841
complications of, 832–833
photographing and marking in, 824–825
postoperative care for, 830–832
preoperative evaluation for, 823–824, 845–846
sedation and anesthesia in, 825–826
sight lines in, 841–845
technique for, 826–830, 846–847
three-dimensional tumescent liposculpture of. See *Three-dimensional tumescent liposculpture.*
Acanthamebiasis, with HIV infection, 455
Accelerator/Eliminator cannula, in liposuction, of calves and ankles, 877
of knees, 872
Acquired progressive lymphangioma, dermatopathology of, 517
Acquired tufted angioma, dermatopathology of, 510
Acral skin, melanocytic neoplasia of, dermatopathology of, 620–621
Adhesion molecules, as markers for malignant melanoma, 637–638
Adnexotropic cutaneous T-cell lymphoma, histology of, 609–610
Alexandrite lasers, long-pulsed, in hair removal. See *Lasers.*
normal mode, in hair removal, 358–359
Alopecia, androgenetic. See *Androgenetic alopecia.*
scarring, immunopathology of, 566–567
Alopecia areata, immunopathology of, 565–566
Amebiasis, military perspective on, 151–154
Aminolevulinic acid, for wound decontamination, 137
in hair removal, 352, 361, 408
Amphotericin-B, for leishmaniasis, 89
Anaplastic large-cell lymphoma, dermatopathology of, 579–580
Ancient nevus, dermatopathology of, 620
Androgenetic alopecia, androgen metabolism in, **245–259**
within skin, 249–253
androgen physiology in, 245–246
castration and, 247–248
clinical features of, 246–247
photographic documentation of, **261–269**
camera settings in, 265–266
camera to patient registration in, 266–267
computer-assisted hair counts in, 268–269
film and processing in, 266
global photography in, 261
housekeeping and archiving in, 267–268
lens type and setting in, 264–265
lighting and exposure control in, 262–264
patient preparation for, 261–262
5α-reductase deficiency and, 248–249
5α-reductase inhibitors for, 253–255
Angiocentric lymphoma, dermatopathology of, 576–577
Angioendothelioma, endovascular papillary, dermatopathology of, 513
Angiofibroma, dermatopathology of, 510–511
Angiogenic factors, as markers for malignant melanoma, 638–639
Angiolymphoid hyperplasia with eosinophilia, dermatopathology of, 509–510
Angioma, acquired tufted, dermatopathology of, 510
Angiosarcoma, dermatopathology of, 515–517
Ankles, liposuction of. See *Calves and ankles.*
Antibiotics, for autoimmune blistering diseases, 435
topical, and contact dermatitis, 710
Anti-fungal drugs, for diaper dermatitis, 238
for leishmaniasis, 89
Anti-inflammatory drugs, for autoimmune blistering diseases, 433–435
for cutaneous injuries, due to chemical warfare agents, 52
Anti-retroviral therapy, highly active, for HIV infection, 445–446
Armed Forces Institute of Pathology, laboratory techniques used by, **125–134**
biophysical, 132–133
confocal microscopy, 132
infrared spectroscopy, 132
magnetic resonance microscopy, 132–133
molecular, 125–132
differential display, 127–128
differential polymerase chain reaction, 127
for infectious diseases, 128–130
for lymphoid neoplasms, 126–127
loss of heterozygosity, 127
nucleic acid sequencing, 127

Armed Forces Institute of Pathology *(Continued)*
routine, 125–126
telomerase research, 130–132
Arms, liposuction of, **783–797**
complications of, 790, 792
preoperative evaluation for, 784–785
technique for, 785–790
Aspergillus infections, with HIV infection, 456–457
Atopic dermatitis, with HIV infection, 460
Autoimmune blistering diseases, electron microscopy of, 697, 701
treatment of, **431–440**
adjuvant therapy in, 433–437
anti-inflammatory drugs, 433–435
immunosuppressants, 435–437
alternative, 437–438
glucocorticoids in, 431–433
Axillary fold, anterior, liposuction of, 801
Azathioprine, for autoimmune blistering diseases, 435–436

Bacillary angiomatosis, dermatopathology of, 515
with HIV infection, 452–453
Back, liposuction of, 801–803
complications of, 803–804
Bacterial infections, with HIV infection. See *HIV infection.*
Balsam of Peru, and contact dermatitis, 709
Basal cell carcinoma, military perspective on. See *Nonmelanoma skin cancer.*
with HIV infection, 463, 464
Basic fibroblast growth factor, as marker for malignant melanoma, 639
B-cell lymphomas. See *Cutaneous lymphomas.*
Bcl–2, as marker for malignant melanoma, 635
in dermatopathology, 678
Beta-blockers, interaction of, with epinephrine, in liposuction, 755–756
Bichloroacetic acid, for condylomata acuminata, 524
Bimoclomol, for cutaneous injuries, due to chemical warfare agents, 52–53
Biologic wound coverings, for thermal burns, 67–68
Biophysical pathology, in military dermatology. See *Armed Forces Institute of Pathology.*
Biopsies, sentinel node, for melanoma, 626–628
skin, for epidermolysis bullosa, 479
Blade slit and graft placement, in follicular unit transplantation, 299, 302–304
Blastomycosis, with HIV infection, 456
Bleached rubber syndrome, diagnosis of, 707
Blistering diseases, autoimmune. See *Autoimmune blistering diseases.*
Blistering drug eruptions. See *Cutaneous drug eruptions.*
Blue nevus, dermatopathology of, 620
Bombesin, in dermatopathology, 677–678
Bowenoid papulosis, dermatopathology of, 524–525
with HIV infection, 463–464
Breslow level, in desmoplastic melanoma, 107
BRST–2/gross cystic disease fluid protein–15, in dermatopathology, 672
Bullous dermatoses, inherited. See *Inherited bullous dermatoses.*
Bupivacaine, in liposuction, 756
Burn centers, **61–75**
nonburn treatment in, 72–74
exfoliative diseases, 72–74
frostbite, 74
necrotizing fasciitis, 74
pemphigus syndromes, 74
thermal burn treatment in, 62–72
admission criteria, 63
biologic wound coverings, 67–68
care of large burns, 65–67
care of small burns, 65
dermal substitutes, 68
donor sites, 69
epidemiology of burns, 62
estimation of severity, 63–65
growth factors, 69
heterotopic ossification, 71–72
hypertrophic scar and keloid formation, 70–71
Marjolin's ulcer, 71
pre-hospital triage, 62–63
rehabilitation, 69–70
skin substitutes, 68
surgical excision, 67
Burn debridement, lasers in, 136
Buschke-Lowenstein tumors, dermatopathology of, 522–523
Buttocks, liposuction of, **815–822**
anatomy in, 818
anesthesia in, 818
complications of, 821
historical aspects of, 815–816
instrumentation for, 817–818
patient education on, 817
patient selection for, 816–817
postoperative care for, 821
technique for, 819–821
marking, 819

Cadaver homografts, for thermal burns, 67
Calves and ankles, liposuction of, 873–877
complications of, 877
preoperative evaluation for, 873–874
technique for, 874–875, 877
Candida infections, and diaper dermatitis, 236
with HIV infection, 455
Carbon dioxide laser therapy, for condylomata acuminata, 524
for cutaneous injuries, due to chemical warfare agents, 53, 56
Carbon dioxide lasers, in burn debridement, 136
Carbon vaporization, in hair removal, 352–353, 408–409
Carcinoembryonic antigen, in dermatopathology, 671–672
Carcinoma, metastatic to skin, dermatopathology of, 679–680
Castration, and androgenetic alopecia, 247–248
Cavernous hemangioma, dermatopathology of, 507–508
Cavitation, in ultrasonic assisted liposuction, 763–764
CD3, in dermatopathology, 678
CD4, in dermatopathology, 678–679
CD8, in dermatopathology, 678–679
CD20, in dermatopathology, 678
CD30, in dermatopathology, 679
CD31, in dermatopathology, 673
CD34, in dermatopathology, 673, 675
CD40, as marker for malignant melanoma, 635–636
CD43, in dermatopathology, 678
CD44, as marker for malignant melanoma, 637
CD56, in dermatopathology, 679
CD68, in dermatopathology, 679
CD99, in dermatopathology, 676
CD1a, in dermatopathology, 679
Cheeks, fat transplantation in, 895

Chemical warfare agents, and cutaneous injuries, **41–60**
absorption in, 43
alkylation in, 43
animal models of, 46–50
gastrointestinal injuries, 45
glutathione levels in, 44
lesion character and severity in, 45
malignancies, 45
optic injuries, 45, 51–52
persistent vs. nonpersistent agents, 42–43
prevention and treatment of, 50–58
respiratory injuries, 45, 52
Chemotherapy, cutaneous effects of, 549–550
for verruca vulgaris, 527
Chest, liposuction of, complications of, 803–804
for anterior axillary fold, 801
Chest and back, liposuction of, **799–804**
for gynecomastia, 799–800
for macromastia, 800–801
Chloride load, in liposuction, 758
Choi implanter, in follicular unit transplantation, 301, 304
Chromogranin, in dermatopathology, 677
Chromos 694 ruby laser, in hair removal, 358
Cimetidine, for verruca plana, 533
c-myc, as marker for malignant melanoma, 633
Coccidioidomycosis, with HIV infection, 456
Cold water immersion foot, and military readiness, 9–11
Collagen alterations, drug-induced, dermatopathology of, 548–550
Condylomata acuminata, dermatopathology of, 522–524
with HIV infection, 449–451
Confocal microscopy, at Armed Forces Institute of Pathology, 132
Congo-Crimean hemorrhagic fever, military perspective on, 34–35
Contact dermatitis, diagnosis of, **705–713**
clues to, 705–706
false-negative, 711–712
generalized dermatitis, 708–710
geographic approach to, 706–708
face, ears, and neck, 706–707
lower extremities, 708
mucosal surfaces, 708
torso, 707
upper extremities, 707–708
iatrogenic dermatitis, 710
Cook Weekend Alternative to Facelift, **773–782**
complications of, 782
indications for, 773–774
postoperative care for, 779, 782
precautions in, 775
preoperative evaluation for, 774–775
results of, 782
technique for, 775–779
anesthesia, 775–776
marking, 775
steps 1 to 10, 776–777, 779
Corticosteroids, for diaper dermatitis, 238
for exfoliative diseases, 73
for thermal burns, 71
Cowden disease, clinical features of, 496
Cryogen spray, in epidermal cooling, in laser hair removal, 349–350
Cryotherapy, for condylomata acuminata, 524
for verruca vulgaris, 527
Cryptococcosis, with HIV infection, 455–456
Curettage and desiccation, for basal cell carcinoma, 95
for nonmelanoma skin cancer, 23
Cutaneous drug eruptions, dermatopathology of, **537–560**
alterations of collagen and elastic fibers, 548–550
blistering, 544–546
linear immunoglobulin A bullous dermatosis, 544
pemphigoid, 545
pemphigus, 545
pseudoporphyria cutanea tarda, 545–546
cytokines and, 556–558
eczematous, 543–544
erythema multiforme, 554
erythroderma, 552
exanthematous, 538
fixed, 539–540
halogenodermas, 551–552
ichthyosiform disorders, 551
interstitial granulomatous, 554–555
lichenoid, 538–539
lupus erythematosus-like eruptions, 546
lymphomatoid, 546–547
photosensitivity, 540–542
pigmentary changes, 552–553
pityriasis rubra pilaris, 555–556
psoriasiform, 553–554
pustular, 542–543
sclerodermoid tissue reactions, 547–548
Stevens-Johnson syndrome, 554
toxic epidermal necrolysis, 554
vasculitis, 550–551
with HIV infection, 461–463
Cutaneous lymphomas, dermatopathology of, **569–592**
B-cell, 580–587
follicle center, 583–585
intravascular, 586–587
large, of leg, 585–586
marginal-zone, 580–583
plasmacytoma, 587
primary, 571–572
T-cell, 572–580
adult lymphoma/leukemia, 574–575
angiocentric, 576–577
lymphomatoid papulosis, 578–579
mycosis fungoides, 572–574
pleomorphic small/medium, 576
primary cutaneous anaplastic large cell, 579–580
subcutaneous panniculitis-like, 577–578
histology of, T-cell, **601–614**
clinical studies of, 601–602, 606–608
clues to, 604–605
early changes in, 602
erythrodermic, 605–606
immunophenotyping in, 611
inflammatory patterns in, 602–603
interface changes in, 603–604
polymerase chain reaction in, 611–612
variants in, 608–611
adnexotropic, 609–610
persistent pigmented purpuric dermatitis, 609
Woringer-Kolopp disease, 610–611
morphology of, B-cell, **593–599**
chronic lymphocytic leukemia/small lymphocytic lymphoma, 594
classification scheme, 593–594
follicle center, 596–597
intravascular, 598
large, of leg, 597–598
lymphoplasmacytoid lymphoma/immunocytoma, 594, 596
mantle-cell, 596
marginal-zone, 597
plasmacytoma, 597
precursor lymphoblastic lymphoma/leukemia, 594

Cutaneous lymphomas *(Continued)*
T-cell–rich, 598
Cutaneous T-cell infiltrates, polymerase chain reaction in, **657–666**
for erythroderma, 662
for follicular mucinosis, 663
for mycosis fungoides, 662
for subcutaneous T-cell lymphoma, 663–664
limitations of, 664
T-cell receptor in, 658–659
techniques for, 659
Cutaneous vascular neoplasms, dermatopathology of, **507–520**
benign, 507–511
acquired tufted angioma, 510
angiofibroma, 510–511
cavernous hemangioma, 507–508
epithelioid hemangioma, 509–510
glomeruloid hemangioma, 509
microvenular hemangioma, 508–509
sinusoidal hemangioma, 508
strawberry nevus, 507
targetoid hemosiderotic hemangioma, 510
verrucous hemangioma, 508
borderline lesions, 511–515
bacillary angiomatosis, 515
epithelioid hemangioendothelioma, 511–512
hemangiopericytoma, 513–514
kaposiform hemangioendothelioma, 512–513
Kaposi's sarcoma, 514–515
malignant endovascular papillary angioendothelioma, 513
polymorphous hemangioendothelioma, 513
retiform hemangioendothelioma, 513
spindle-cell hemangioendothelioma, 511
lymphatic lesions, 517
malignant, 515–517
angiosarcoma, 515–517
epithelioid angiosarcoma, 517
Cyclophosphamide, for autoimmune blistering diseases, 436
Cyclosporine, for autoimmune blistering diseases, 436
Cytokeratin, in dermatopathology, 667–668
Cytokine therapy. and cutaneous drug eruptions, dermatopathology of, 556–558
Cytomegalovirus infection, with HIV infection, 448–449

Dapsone, for autoimmune blistering diseases, 433–434
Dengue, military perspective on, 31–32
Dengue hemorrhagic fever, military perspective on, 31
Dengue shock syndrome, military perspective on, 31
Depilatories, in hair removal, 373
Dermal augmentation, fat transplantation in, 893
Dermal substitutes, for thermal burns, 68
DermaLase, in hair removal, 413
Dermatitis, contact. See *Contact dermatitis.*
diaper. See *Diaper dermatitis.*
persistent pigmented purpuric, histology of, 609
with HIV infection, 457, 460–461
Dermatofibroma, extending into subcutaneous tissue, histopathology of, 487–488
with atypical cells, histopathology of, 488–491
Dermatofibrosarcoma protuberans, military perspective on, 103–105
plaque stage of, histopathology of, 499–501
Dermatomyofibroma, histopathology of, 494–496
Dermatopathology, electron microscopy in. See *Electron microscopy.*
immunohistochemistry in. See *Immunohistochemistry.*
of cutaneous drug eruptions. See *Cutaneous drug eruptions.*
of cutaneous lymphomas. See *Cutaneous lymphomas.*
of cutaneous T-cell infiltrates. See *Cutaneous T-cell infiltrates.*
of cutaneous vascular neoplasms. See *Cutaneous vascular neoplasms.*
of fibrous and fibrohistiocytic tumors. See *Fibrous tumors.*
of HIV infection. See *HIV infection.*
of human papillomavirus infection. See *Human papillomavirus infection.*
of inherited bullous dermatoses. See *Inherited bullous dermatoses.*
of malignant melanoma. See *Malignant melanoma.*
of melanocytic neoplasia. See *Melanocytic neoplasia.*
Dermatoses, inherited bullous. See *Inherited bullous dermatoses.*
Desmin, in dermatopathology, 668–669
Desmoplastic melanoma, dermatopathology of, 621–624
military perspective on, 106–108
Desmoplastic nevus, dermatopathology of, 617
Diaper dermatitis, **235–240**
Candida in, 236
diagnosis of, 236–237
diaper as cause of, 235–236
generic, 236
miliaria rubra in, 236
treatment of, 237–239
air in, 237
barriers in, 237–238
choice of diaper in, 238–239
cleansing in, 238
education in, 239
Diode lasers, in hair removal, 359–360
Discoid lupus erythematosus, and scarring alopecia, immunopathology of, 566
Drug eruptions. See *Cutaneous drug eruptions.*
Dutcher bodies, in marginal-zone lymphoma, 581–582
Dystrophic epidermolysis bullosa, dermatopathology of of, 477–479

Ectoparasitic infections, with HIV infection. See *HIV infection.*
Eczematous drug eruptions, dermatopathology of, 543–544
Elastic fiber alterations, drug-induced, dermatopathology of, 548–550
Electrochemistry, and tattoo removal, 141
Electrolysis, in hair removal, 373
Electron microscopy, in dermatopathology, **691–704**
double labeling in, 701, 703
materials and methods for, 692
of autoimmune bullous diseases, 697, 701
of epidermolysis bullosa, 479–480
of genetic diseases, 701
pre-embedding vs. post-embedding in, 691–692
to complement case studies, 692–693
with immunohistochemistry, 693, 697
Endothelial markers, in dermatopathology, 673
Endovascular papillary angioendothelioma, dermatopathology of, 513
Environmental skin diseases, and military readiness, **1–17**
elemental factors in, 2–12
air, 4–9
earth, 2

fire, 2–4
water, 9–12
disqualifying, for military service, 12–14, 17
Eosinophilic folliculitis, with HIV infection, 459–460
Epidermal cooling, in laser hair removal, 347–350
Epidermal growth factor, in hair follicle culture, 322
Epidermal-derived tissue, for thermal burns, 68
Epidermodysplasia verruciformis, dermatopathology of, 527–529
Epidermolysis bullosa. See *Inherited bullous dermatoses.*
Epidermolysis verruciformis, with HIV infection, 463, 464
Epidermotropic metastatic melanoma, dermatopathology of, 624
Epidermotropism, in mycosis fungoides, 573
Epilaser, in hair removal, 358, 412
EpiLight, in hair removal, 360, 377
Epinephrine, in liposuction, 753–756
Epithelial membrane antigen, in dermatopathology, 671
Epithelioid angiosarcoma, dermatopathology of, 517
Epithelioid cell histiocytoma, histopathology of, 492–494
Epithelioid cell nevus, dermatopathology of, 617
Epithelioid hemangioendothelioma, dermatopathology of, 511–512
Epithelioid hemangioma, dermatopathology of, 509–510
Epitouch, in hair removal, 358
Epitouch ALEX, in hair removal, 359
Epstein-Barr virus, with HIV infection, 449
Erythema ab igne, and military readiness, 3
Erythema multiforme, dermatopathology of, 554
Erythroderma, drug-induced, dermatopathology of, 552
polymerase chain reaction in, 662
Escharotomy, for thermal burns, 67
Esophageal strictures, with epidermolysis bullosa, 482
Exanthemous drug eruptions, dermatopathology of, 538
Exfoliative diseases, treatment of, in burn centers, 72–74
Exo-antigens, in leishmaniasis, 87
Exotic viral infections, military perspective on, **29–40**
Congo-Crimean hemorrhagic fever, 34–35
dengue, 31–32
hemorrhagic fever viruses, 29–31
hemorrhagic fever with renal syndrome, 32, 34
pox virus infections, 35–39
monkeypox, 36–37
smallpox, 35–36
vaccinia, 37

Factor VIII–related antigen, in dermatopathology, 673
Factor XIIIa, in dermatopathology, 675
Fas (Apo–1/CD95), as marker for malignant melanoma, 639–640
Fat transplantation, **891–898**
anatomy in, 893–896
cheeks, 895
hands, 896
lipodystrophy, 895
liposuction defects, 896
lips, 894–895
malar area, 895
nasolabial furrows, 893–894
traumatic lipodystrophy, 895–896
complications of, 898
future of, 898
histology of, 896–898
historical aspects of, 725–726
indications for, 891–892
lipocytic dermal augmentation, 893
technique for, 892–893

Fibrohistiocytic markers, in dermatopathology, 673–675
Fibrohistiocytic tumors. See *Fibrous tumors.*
Fibroma, pleomorphic, of skin, histopathology of, 491–492
sclerotic, of skin, histopathology of, 496–498
Fibrosarcoma, histopathology of, 501–504
Fibrous tumors, histopathology of, **487–505**
atypical fibroxanthoma, 498–499
dermatofibroma extending subcutaneously, 487–488
dermatofibroma with atypical cells, 488–491
dermatomyofibroma, 494–496
epithelioid cell histiocytoma, 492–494
fibrosarcoma, 501–504
plaque stage of dermatofibrosarcoma protuberans, 499–501
pleomorphic fibroma of skin, 491–492
sclerotic fibroma of skin, 496–498
Fibroxanthoma, atypical, histopathology of, 498–499
military perspective on, 105
Finasteride, for androgenetic alopecia, 253–255
Fixed drug eruptions, dermatopathology of, 539–540
Flanks, three-dimensional tumescent liposculpture of. See *Three-dimensional tumescent liposculpture.*
Flaps, in hair restoration, follicular units in, 291
Flat condyloma, dermatopathology of, 522–524
Fluid homeostasis, in liposuction, 757
5-Fluorouracil, for condylomata acuminata, 524
Focal epithelial hyperplasia, dermatopathology of, 529–530
Follicle center lymphoma, dermatopathology of, 583–585
morphology of, 596–597
Follicular lymphoid infiltrates, immunopathology of, 565
Follicular mucinosis, polymerase chain reaction in, 663
Follicular unit transplantation, **277–295**
follicle trauma in, **307–313**
clinical studies of, 307–308
prevention of, microscopy in, 311
historical aspects of, 277–280
donor supply, 278–280
punch graft technique, 277–278
logic of automation, 293–294
logic of creating sites with cold steel, 283–284
logic of follicular unit constant, 288–292
characteristics of follicular unit, 291–292
mathematics in, 290–291
scalp reductions and flaps, 291
logic of microscopic dissection, 293
logic of preserving follicular unit, 280
logic of single strip harvesting, 292–293
logic of small recipient sites, 282–283
logic of transplanting in large sessions, 284–288
complexion of follicular units, 287–288
economizing donor supply, 286–287
planning for telogen effluvium, 285–286
logic of transplanting individual units, 281–282
techniques for, **297–306**
Choi implanter, 301, 304
comparison of, 301–304
costs of, 304–305
separated needle stick and graft placement, 299, 301, 304
simultaneous blade slit and graft placement, 299, 302–304
simultaneous needle stick and graft placement, 298–299, 302
Folliculitis, eosinophilic, with HIV infection, 459–460
immunopathology of, 564
with HIV infection, 451

Formaldehyde, and contact dermatitis, 709–710
Foscarnet, hypersensitivity to, in HIV-infected patients, 462
Frostbite, and military readiness, 4–9
  treatment of, in burn centers, 74
    rewarming in, 6–7
    sympathectomy in, 8
    thrombolytic therapy in, 8
Fungal infections, with HIV infection. See *HIV infection.*

Gastrointestinal injuries, chemical warfare agents and, 45
Gene therapy, for epidermolysis bullosa, 482–483
Generalized atrophic epidermolysis bullosa, dermatopathology of, 477
Genetic diseases, electron microscopy of, 701
Genital herpes, with HIV infection, 447–448
Genital lesions, due to human papillomavirus, 522–524
Genitalia, female, melanoma of, dermatopathology of, 625
GentleLASE, in hair removal, 359
Giant condyloma, dermatopathology of, 522–524
Glial fibrillary acidic protein, in dermatopathology, 669–670
Glomeruloid hemangioma, dermatopathology of, 509
Glucocorticoids, for autoimmune blistering diseases, 431–433
  topical, and contact dermatitis, 710
Gold therapy, for autoimmune blistering diseases, 434–435
Graft-vs.-host disease, and scarring alopecia, immunopathology of, 566
Granulocyte colony-stimulating factor, and cutaneous drug eruptions, dermatopathology of, 556
Granulocyte-macrophage colony-stimulating factor, and cutaneous drug eruptions, dermatopathology of, 556
Gravis variant, of junctional epidermolysis bullosa, 477
Growth factors, and wound healing, in thermal burns, 69
  in hair follicle culture, 321–324
Gynecomastia, liposuction for, 799–800

Hair abnormalities, with HIV infection, 463
Hair follicle culture, **315–329**
  future of, 326
  growth factors in, 321–324
  histoculture in, 326
  in animals, 325–326
  in rodents, 324–325
  metabolic studies of, 324
  microdissection in, 316–317
  modified microdissection in, 316
  shearing in, 316
  technique for, 317, 320–321
Hair follicles, immunopathology of, **561–568**
    follicular lymphoid infiltrates, 565
    in alopecia areata, 565–566
    in folliculitis, 564
    in scarring alopecia, 566–567
    normal follicles, 561–564
Hair removal, aminolevulinic acid in, 352, 361, 408
  carbon vaporization in, 352–353, 408–409
  Chromos 694 ruby laser in, 358
  Epilaser in, 358, 412
  EpiLight in, 360, 377
  Epitouch ALEX in, 359
  Epitouch in, 358
  GentleLASE in, 359
  lasers in. See *Lasers.*
  pulsed-intense light sources in. See *Pulsed-intense light sources.*
  SoftLight System in, 360–361, 410–413
Hair restoration, follicular unit transplantation in. See *Follicular unit transplantation.*
  hairline creation in, **271–276**
    grafts in, 274–275
    hairline shape in, 273
    hairline site in, 273
    initial consultation for, 271–273
    postoperative care for, 275
    rules of design in, 273–274
Halogenodermas, drug-induced, dermatopathology of, 551–552
Hands, fat transplantation in, 896
Heat exhaustion, and military readiness, 3
Heat stroke, and military readiness, 3
Hemangioendotheliomas, dermatopathology of. See *Cutaneous vascular neoplasms.*
Hemangiomas, dermatopathology of. See *Cutaneous vascular neoplasms.*
Hemangiopericytoma, dermatopathology of, 513–514
Hematopoietic differentiation markers, in dermatopathology, 678–679
Hemorrhagic fever viruses, military perspective on, 29–31
Hemorrhagic fever with renal syndrome, military perspective on, 32, 34
Herlitz variant, of junctional epidermolysis bullosa, 477
Hernia, umbilical, and abdominal liposuction, 829
Herpes zoster, with HIV infection, 448
Herpesvirus infections, and Kaposi's sarcoma, 465, 515
  with HIV infection, 447–448
Heterotopic ossification, thermal burns and, 71–72
Hirsutism, laser therapy for. See *Lasers.*
Histiocytoma, epithelioid cell, histopathology of, 492–494
  malignant fibrous, military perspective on, 105–106
Histoplasmosis, with HIV infection, 456
HIV infection, cutaneous features of, **445–471**
    bacterial infections, 451–454
      bacillary angiomatosis, 452–453
      folliculitis, 451
      impetigo, 451–452
      mycobacterial, 453
      syphilis, 453–454
    neoplasms, 463–467
      Kaposi's sarcoma, 465–467
      lymphoreticular, 464–465
      primary, 463–464
    noninfectious, 457–463
      atopic dermatitis, 460
      drug eruptions, 461–463
      eosinophilic folliculitis, 459–460
      hair and nail abnormalities, 463
      porphyria cutanea tarda, 461
      prurigo nodularis, 458–459
      psoriasis, 457–458
      Reiter's syndrome, 458
      seborrheic dermatitis, 457
      urticaria, 461
      xerotic dermatitis, 460–461
    parasitic and ectoparasitic infections, 454–455
      acanthamebiasis, 455
      pneumocystosis, 454–455
      scabies, 454

strongyloidiasis, 455
systemic fungal infections, 455–457
Aspergillus, 456–457
blastomycosis, 456
coccidioidomycosis, 456
cryptococcosis, 455–456
histoplasmosis, 456
Penicillium marneffei, 457
sporotrichosis, 456
viral infections, 447–451
acute exanthem, 447
cytomegalovirus, 448–449
herpesviruses, 447–448
human papillomavirus, 449–451
molluscum contagiosum, 451
oral hairy leukoplakia, 449
pathogenesis of, 446–447
response of, to anti-retroviral therapy, 445–446
HMB–45, in dermatopathology, 675
Hobnail hemangioma, dermatopathology of, 510
Hodgkin's disease, with HIV infection, 464–465
Homing receptors, as markers for malignant melanoma, 637–638
Homografts, for thermal burns, 67
Human papillomavirus infection, dermatopathology of, **521–536**
bowenoid papulosis, 524–525
deep palmoplantar warts, 530–531
epidermodysplasia verruciformis, 527–529
focal epithelial hyperplasia, 529–530
genital lesions, 522–524
verruca plana, 531–533
verruca vulgaris, 525–527
molecular aspects of, 521–522
with HIV infection, 449–451
Hypermelanotic nevus, dermatopathology of, 620
Hyperpigmentation, after laser therapy, for hair removal, 397–398
Hypertrichosis, laser therapy for. See *Lasers*.
Hypertrophic scars, thermal burns and, 70–71

Ichthyosiform disorders, drug-induced, dermatopathology of, 551
Imiquimod, for condylomata acuminata, 524
Immunocytoma, morphology of, 594, 596
Immunofluorescent microscopy, of epidermolysis bullosa, 480
Immunoglobulin, intravenous, for autoimmune blistering diseases, 438
Immunohistochemistry, in dermatopathology, **667–689**
BRST–2/gross cystic disease fluid protein–15 in, 672
carcinoembryonic antigen in, 671–672
differentiation of carcinoma metastatic to skin, 679–680
endothelial markers in, 673
epithelial membrane antigen in, 671
fibrohistiocytic and macrophage markers in, 673–675
hematopoietic differentiation markers, 678
intermediate filaments in, 667–671
cytokeratin, 667–668
desmin, 668–669
glial fibrillary acidic protein, 669–670
nestin, 670–671
neurofilaments, 670
peripherin, 669
vimentin, 668
muscle actin in, 672–673
neuroectodermal markers in, 675–677
neuroendocrine differentiation markers in, 677–678
with electron microscopy, 693, 697
Immunophenotyping, of cutaneous T-cell lymphoma, 611
Immunoregulatory molecules, as markers for malignant melanoma, 639–640
Immunosuppressants, for autoimmune blistering diseases, 435–437
Immunosuppression, and human papillomavirus infection, 523
effect of, on squamous cell carcinoma, 97–99
Impetigo, with HIV infection, 451–452
Infections, exotic viral. See *Exotic viral infections*.
systemic signs of, in thermal burns, 66–67
Infectious and parasitic diseases, diagnosis of, Armed Forces Institute of Pathology techniques for, 128–130
military perspective on, **151–185**
cutaneous amebiasis, 151–154
cutaneous leishmaniasis. See *Leishmaniasis*.
cutaneous myiasis, 182–184
cutaneous schistosomiasis, 160–163
cutaneous sporotrichosis, 172–173
Micrococcus infections, 167–168
Mycobacterium ulcerans infection, 164, 166–167
primary cutaneous nocardiosis, 168, 170–172
sparganosis, 163–164
streptocerciasis, 155–156, 158–160
subcutaneous phaeohyphomycosis, 173–177
subcutaneous zygomycosis, 177–179
tungiasis, 179–180
Infrared spectroscopy, at Armed Forces Institute of Pathology, 132
Inherited bullous dermatoses, dermal-epidermal basement membrane in, 473–474
dermatopathology of, **473–485**
dystrophic epidermolysis bullosa, 477–479
epidermolysis bullosa simplex, 475–476
epidermolysis bullosa with muscular dystrophy, 476
epidermolysis bullosa with pyloric atresia, 476
junctional epidermolysis bullosa, 477
diagnosis of, 479–480
treatment of, 480–482
gene therapy in, 482–483
Insulin, in hair follicle culture, 320, 321–322
Insulin-like growth factor, in hair follicle culture, 320, 322
Integrin $\alpha v\beta 3$, as marker for malignant melanoma, 637–638
Interferons, and cutaneous drug eruptions, dermatopathology of, 556, 558
for condylomata acuminata, 524
for verruca vulgaris, 527
Interleukins, in hair follicle culture, 323–324
Intermediate filaments, in dermatopathology, 667–671
Interstitial granulomatous drug eruptions, dermatopathology of, 554–555
Intravascular B-cell lymphoma, dermatopathology of, 586–587
morphology of, 598

Junctional epidermolysis bullosa, dermatopathology of of, 477
Juvenile hemangioendothelioma, dermatopathology of, 507

Kala-azar, military perspective on, 81, 154–155
Kaposiform hemangioendothelioma, dermatopathology of, 512–513
Kaposi's sarcoma, dermatopathology of, 514–515
with HIV infection, 465–467
Keloids, thermal burns and, 70–71
Ki-67 antigen, as marker for malignant melanoma, 632–633
Knees, liposuction of, 865–873
complications of, 872–873
preoperative evaluation for, 867, 869–870
technique for, 870–872

Lactated Ringer's solution, in liposuction, 757–758
Laser therapy, for condylomata acuminata, 524
for verruca vulgaris, 526–527
military perspective on, **135–150**
for burn debridement, 136
for cutaneous injuries, due to chemical warfare agents, 53, 56
for pseudofolliculitis barbae, 141–144
for subsurface imagery, 145–147
for tattoo removal, 137–141
for tissue welding, 144–145
for wound decontamination, 136–137
Lasers, in follicular unit transplantation, 283–284
in hair removal, **333–355**, **357–366**, 377
anesthesia in, 362
broad band source in, 345
causes of excess hair growth, 357–358
compacting dermis in, 345
diode lasers, 359–360
embryology and anatomy in, 333–337
depth of bulb, 335
hair color, 335–336
hair growth cycles, 334
location of target, 336–337
types of hair, 335
epidermal cooling in, 347–350
fluence setting in, 363
focusing beam in, 345
follicle biology in, 352
hair color and, 362
high-powered Q-switched Nd:YAG lasers, 360
immediate response to, 363
long-pulsed alexandrite lasers, **387–399**, 412
embryology and anatomy in, 387–389
for hypertrichosis and hirsutism, 390–391
hair growth physiology in, 389–390
hyperpigmentation after, 397–398
postoperative care for, 398
preoperative preparation for, 396
technique for, 392–398
with selective thermolysis, 391–392
long-pulsed ruby lasers, **367–372**
contraindications to, 368
efficacy of, 371
mechanism of action of, 367–368
patient expectations of, 369, 371
postoperative care for, 369
side effects of, 369
technique for, 368–369
Nd:YAG lasers, **401–430**
beam size and repetition rate in, 411–412
choosing target in, 406–408
chromophore in, 408–409
clinical studies of, 412–420
epidemiology of, 403–405
function of, 402
future of, 427–428
hair structure and function in, 405–406
histology of, 420–423
historical aspects of, 401
patient history in, 425
postoperative care for, 427
preoperative evaluation for, 423, 425–426
pulse duration in, 409–411
Q-switched, 360
rationale for, 402–403
skin preparation for, 426
wavelength in, 409
normal mode alexandrite lasers, 358–359
normal mode ruby lasers, 358
number of sessions in, 350, 352
optimal wavelength in, 350
pain in, 350
patient expectations and outcome in, 364–365
patient history in, 361
physical basis for, 337–344
analysis of beam propagation in tissue, 338–341
analysis of optical and thermal properties, 341–343
heat diffusion, 343–344
postoperative care for, 363–364
preoperative instructions for, 361–362
pulse duration and multiple pulses in, 346–347
pulsed-intense light sources in. See *Pulsed-intense light sources.*
safety of, 362
side effects of, 364
skin color and, 362
spot diameter in, 344–345
technique for, 363
treatment intervals in, 364
Legs, large B-cell lymphoma of, dermatopathology of, 585–586
morphology of, 597–598
Leishmaniasis, military perspective on, **77–92**, 154–155
clinical features, 79–82
diagnosis, 85–87
historical aspects, 77–78
parasite life cycle, 78–79
pathogenesis, 84–85
transmission, 82–84
treatment, 88–89
Leu-7, in dermatopathology, 676–677
Leukemia, adult, dermatopathology of, 574–575
Lewisite. See *Chemical warfare agents.*
Lichen planopilaris, and scarring alopecia, immunopathology of, 566
Lichenoid drug eruptions, dermatopathology of, 538–539
Lidocaine, in liposuction, 753–756
Light chains, in dermatopathology, 678
Linear immunoglobulin A bullous dermatosis, dermatopathology of, 544
Liposculpture, three-dimensional. See *Three-dimensional tumescent liposculpture.*
Liposuction, Cook Weekend Alternative to Facelift in. See *Cook Weekend Alternative to Facelift.*
defects due to, fat transplantation for, 896
historical aspects of, 723–725
indications for, 730
instrumentation for, **735–749**
ancillary equipment, 746–747
aspiration equipment, 739
mechanical pumps, 740
cannulas, 741–744

cleaning of, 744
collection devices and filters, 741
for infusing tumescent solution, 735–737
needles, 737, 739
for warming tumescent solution, 736
monitoring equipment, 745–746
postoperative garments, 747–748
sterile operating theater, 744–745
ultrasound, intraoperative, 740–741
postoperative, 748–749
morbidity and mortality from, **899–902**
actions regarding, 901
board certification and, 901
risk factors for, 900
semitumescent liposuction in, 899
statistics on, 899–900
tumescent anesthesia in, 899
tumescent liposuction in, 899
venue and, 901
of abdomen. See *Abdomen.*
of arms. See *Arms.*
of back, 801–803
complications of, 803–804
of calves and ankles. See *Calves and ankles.*
of chest. See *Chest.*
of female buttocks. See *Buttocks.*
of knees. See *Knees.*
of posterior neck, 803
of thighs. See *Thighs.*
patient selection for, 730
postoperative care for, **881–889**
adits in, 885, 887
antiquated use of sutures, 885
compression sponges in, 884–885, 888–889
graduated vs. bimodal, 889
historical aspects of, 888
prolonged use of, 888–889
eliminating sutures in, 887–888
for edema, 881–882
for excess capillary filtration, 882
for lymphedema, 882–884
antiquated techniques, 883–884
effects on lymphatics, 882–883
lymph flow and interstitial fluid pressure, 883
lymphatic pump mechanism, 883
microscopic structure of lymphatics, 882
normal lymphatic function, 882
wound fluid osmolality, 883
lymphatic drainage in, 882
open drainage in, 884
preoperative evaluation for, 731–733
preoperative laboratory tests for, 733
tumescent solutions in. See *Tumescent solutions.*
ultrasonic assisted. See *Ultrasonic assisted liposuction.*
Lips, fat transplantation in, 894–895
Long-pulsed alexandrite lasers, in hair removal. See *Lasers.*
Long-pulsed ruby lasers, in hair removal. See *Lasers.*
Lupus erythematosus–like drug eruptions, dermatopathology of, 546
Lymph node dissection, for Merkel cell carcinoma, 101
for squamous cell carcinoma, 99
Lymphadenectomy, sentinel, for malignant melanoma. See *Malignant melanoma.*
Lymphangioma, acquired progressive, dermatopathology of, 517
Lymphedema, liposuction and. See *Liposuction.*
Lymphoblastic lymphoma/leukemia, morphology of, 594
Lymphocytic leukemia, morphology of, 594
Lymphocytic lymphoma, morphology of, 594
Lymphoid neoplasms, diagnosis of, Armed Forces Institute of Pathology techniques for, 126–127
Lymphomas, cutaneous. See *Cutaneous lymphomas.*
subcutaneous T-cell, polymerase chain reaction in, 663–664
Lymphomatoid drug eruptions, dermatopathology of, 546–547
Lymphomatoid papulosis, dermatopathology of, 578–579
Lymphoplasmacytoid lymphoma/immunocytoma, morphology of, 594, 596
Lymphoreticular malignancies, with HIV infection, 464–465
Lymphoscintigraphy, before sentinel lymphadenectomy, for malignant melanoma, 646–647

Macromastia, liposuction for, 800–801
Macrophage markers, in dermatopathology, 673–675
Magnetic resonance microscopy, at Armed Forces Institute of Pathology, 132–133
Malar area, fat transplantation in, 895
Malignancies, chemical warfare agents and, 45
Malignant melanoma, markers for, **631–643**
angiogenic factors, 638–639
Bcl-2, 635
CD40, 635–636
CD44, 637
c-myc, 633
immunoregulatory molecules, 639–640
integrin $\alpha v\beta 3$, 637–638
Ki-67 antigen, 632–633
matrix-degrading enzymes, 636
melanoma cell adhesion molecule, 638
p53, 634
$p16^{INK4a}$, 633–634
$p21^{WAF1}$, 634–635
sentinel lymphadenectomy for, **645–655**
false-negative, 650–651
intraoperative mapping for, 647–649
pathologist's role in, 649–650
preoperative mapping for, 646–647
prognostic value of, 651
rationale for, 646
therapeutic impact of, 651, 654
with HIV infection, 463
Mantle-cell lymphoma, morphology of, 596
Marginal-zone lymphoma, dermatopathology of, 580–583
morphology of, 597
Marjolin's ulcer, metastatic, 97
thermal burns and, 71
treatment of, 99
MART-1, in dermatopathology, 676
Matrix-degrading enzymes, as markers for malignant melanoma, 636
Medical assistance missions, **187–208**
and dermatology, in developing countries, 190–191
and hyperendemic conditions, 196
communications in, 200–201
completion of, 202
customs and courtesies on, 193–194
dermatologic formularies in, 196–197
donated drugs for, 197–198
in refugee camps, 199–200
language assistance in, 194–195
phrase guide for, 208
military participation in, statutory background of, 203

Medical assistance missions *(Continued)*
organization affiliations in, 189–190
packing list for, 192–193, 205–207
airplane bag, 205
documents, 205–206
gender-specific items, 207
health and hygiene, 206
items for local hosts, 207
items to avoid, 207
medical items, 206–207
military items, 207
Peace Corps additions, 207
safety, 206
sleeping gear, 206
philosophical considerations in, 188–189
photography in, 201–202
preparation for, 191–192
home arrangements, 204
legal, financial, and administrative, 203
military additions, 205
passports, visas, and permits, 204
Peace Corps additions, 205
personal medical issues, 204
public affairs/media relations, 204
transportation and communication, 204
safety of, 193
set-up of, 195–196
surgical procedures and biopsies in, 198–199
veterinary and dental support in, 200
MedLite laser, in hair removal, 413
Mel–5, in dermatopathology, 675–676
Melanin, and laser hair removal, 358, 408
Melanocytic neoplasia, dermatopathology of, **615–630**
ancient nevus, 620
atypical nevus and melanocytic dysplasia, 616–617
blue nevus and its variants, 620
deep penetrating nevus, 620
desmoplastic, neurotropic, and spindle-cell melanoma, 621–624
desmoplastic nevus, 617
epidermotropic metastatic melanoma, 624
hypermelanotic nevus, 620
immunohistochemistry in, 615–616
in children, 621
melanoma of female genitalia, 625
of acral skin, 620–621
pigmented spindle-cell nevus, 617, 620
spindle- and epithelioid-cell nevus, 617
verrucous melanoma, 624
resection of, margins for, 625–626
sentinel node biopsy for, 626–628
Melanoma, desmoplastic, military perspective on, 106–108
malignant. See *Malignant melanoma.*
nevoid malignant, military perspective on, 108
Melanoma cell adhesion molecule, as marker for malignant melanoma, 638
Merkel cell carcinoma, military perspective on, 99–101
Metalloproteinases, matrix, as markers for malignant melanoma, 636
Methotrexate, for autoimmune blistering diseases, 436–437
MIB–1, in dermatopathology, 679
Micrococcus infections, military perspective on, 167–168
Microcystic adnexal carcinoma, military perspective on, 102–103
Microvenular hemangioma, dermatopathology of, 508–509
Miliaria rubra, and diaper dermatitis, 236
Military dermatology, Armed Forces Institute of Pathology in. See *Armed Forces Institute of Pathology.*
chemical warfare agents in. See *Chemical warfare agents.*
environmental skin diseases in. See *Environmental skin diseases.*
exotic viral infections in. See *Exotic viral infections.*
in burn centers. See *Burn centers.*
in medical assistance missions. See *Medical assistance missions.*
infectious and parasitic diseases in. See *Infectious and parasitic diseases.*
laser therapy in. See *Laser therapy.*
leishmaniasis in. See *Leishmaniasis.*
nonmelanoma skin cancer in. See *Nonmelanoma skin cancer.*
role of, **209–234**
entering active duty, 210–212
in Cuba, 220–226
in Haiti, 216–217, 220
in humanitarian missions, 228–229, 234. See also *Medical assistance missions.*
in Pacific theater, 226–228
in Persian Gulf War, 212–213, 216
skin cancer in. See *Skin cancer.*
teledermatology in. See *Teledermatology.*
Mitten deformity, with epidermolysis bullosa, 482
Mohs micrographic surgery, for basal cell carcinoma, 95–96
for dermatofibrosarcoma protuberans, 105
for melanoma, 625–626
for nonmelanoma skin cancer, 23–27
for squamous cell carcinoma, 98–99
Molecular biology, in military dermatology. See *Armed Forces Institute of Pathology.*
Molluscum contagiosum, with HIV infection, 451
Monkeypox, military perspective on, 36–37
Monoclonal antibodies, against leishmaniasis, 86
Monocytoid B-cell lymphoma, dermatopathology of, 580–583
Montenegro test, for leishmaniasis, 85
Morbilliform drug eruptions, dermatopathology of, 538
Motility factors, as markers for malignant melanoma, 637–638
Mucinosis, follicular, polymerase chain reaction in, 663
Multiple hamartoma syndrome, clinical features of, 496
Muscle actin, in dermatopathology, 672–673
Muscular dystrophy, epidermolysis bullosa with, 476
Mycobacterial infections, with HIV infection, 453
Mycobacterium ulcerans infection, military perspective on, 164, 166–167
Mycophenolate mofetil, for autoimmune blistering diseases, 437
Mycosis fungoides, dermatopathology of, 572–574
polymerase chain reaction in, 662
Myiasis, military perspective on, 182–184
Myramecial warts, dermatopathology of, 530–531

Nail abnormalities, with HIV infection, 463
Nasolabial furrows, fat transplantation in, 893–894
Nd:YAG lasers, in hair removal. See *Lasers.*
Neck, posterior, liposuction of, 803
Necrotizing fasciitis, treatment of, in burn centers, 74
Needle stick and graft placement, in follicular unit transplantation, 298–299, 302
Neoplasia, melanocytic. See *Melanocytic neoplasia.*
Neoplasms, with HIV infection. See *HIV infection.*
Nestin, in dermatopathology, 670–671
Neuroectodermal markers, in dermatopathology, 675–677

Neuroendocrine differentiation markers, in dermatopathology, 677–678
Neurofilaments, in dermatopathology, 670
Neurotropic melanoma, dermatopathology of, 621–624
Neutropenia, exfoliative diseases and, 73
Nevi, melanocytic. See *Melanocytic neoplasia.*
Nevoid malignant melanoma, military perspective on, 108
Nickel, and contact dermatitis, 710
Nitrogen mustard. See *Chemical warfare agents.*
Nocardiosis, military perspective on, 168, 170–172
Nodal nevus, in melanoma, 626, 628
Non-Hodgkin's lymphoma, with HIV infection, 464–465
Nonmelanoma skin cancer, military perspective on, **19–28**, 93–96
  diagnosis, 19–22
  treatment, 22–23
    cost analysis of, 24–27
    Mohs micrographic surgery, 23–27
Normal saline, in liposuction, 753, 757
Nucleic acid sequencing, at Armed Forces Institute of Pathology, 127

Opioids, in HIV-infected patients, and prurigo nodularis, 458–459
Optic injuries, chemical warfare agents and, 45, 51–52
Oral hairy leukoplakia, with HIV infection, 449
Osteoporosis, glucocorticoids and, 432

p53, as marker for malignant melanoma, 634
Palmoplantar warts, dermatopathology of, 530–531
Panniculitis-like T-cell lymphoma, dermatopathology of, 577–578
Papillary angioendothelioma, endovascular, dermatopathology of, 513
Papular urticaria, with HIV infection, 461
Parasitic diseases. See *Infectious and parasitic diseases.*
  with HIV infection. See *HIV infection.*
Pautrier's microabscesses, in mycosis fungoides, 573
Pemphigoid, drug-induced, dermatopathology of, 545
Pemphigus, drug-induced, dermatopathology of, 545
Pemphigus syndromes, treatment of, in burn centers, 74
Penicillium marneffei infections, with HIV infection, 457
Pentamidine, for leishmaniasis, 89
Peripherin, in dermatopathology, 669
  in melanocytic neoplasia, 616
Periumbilical area, liposuction of, 829
Persistent pigmented purpuric dermatitis, histology of, 609
Petrolatum, for diaper dermatitis, 238
Phaeohyphomycosis, military perspective on, 173–177
Photoallergic reactions, of face, ears, and neck, 706
PhotoDerm VI, in hair removal. See *Pulsed-intense light sources.*
Photodynamic therapy, for wound decontamination, 137
Photophoresis, for autoimmune blistering diseases, 437–438
Photosensitivity disorders, and military readiness, 3
Photosensitivity drug eruptions, dermatopathology of, 540–542
Pigmentary changes, drug-induced, dermatopathology of, 552–553
Pigmented spindle-cell nevus, dermatopathology of, 617, 620
$p16^{INK4a}$, as marker for malignant melanoma, 633–634
Pityriasis rubra pilaris, drug-induced, dermatopathology of, 555–556
Plaque stage, of dermatofibrosarcoma protuberans, histopathology of, 499–501
Plasmacytoma, dermatopathology of, 587
  morphology of, 597
Plasmapheresis, for autoimmune blistering diseases, 437
Plasminogen activator system, as marker for malignant melanoma, 636
Pleomorphic cutaneous T-cell lymphoma, dermatopathology of, 576
Pleomorphic fibroma, of skin, histopathology of, 491–492
Pneumocystosis, with HIV infection, 454–455
Podophyllin, for condylomata acuminata, 524
POEMS syndrome, glomeruloid hemangioma in, 509
Polymerase chain reaction, in cutaneous T-cell infiltrates. See *Cutaneous T-cell infiltrates.*
  in cutaneous T-cell lymphoma, 611–612
  in mycosis fungoides, 574
  uses for, at Armed Forces Institute of Pathology, 127
    in leishmaniasis, 87
Polymorphous hemangioendothelioma, dermatopathology of, 513
Porphyria cutanea tarda, with HIV infection, 461
Pox virus infections, military perspective on. See *Exotic viral infections.*
Prednisone, for autoimmune blistering diseases, 437
Protease dysregulation, for cutaneous injuries, due to chemical warfare agents, 56, 58
Protease inhibitors, hypersensitivity to, in HIV-infected patients, 462
Prurigo nodularis, with HIV infection, 458–459
Pseudofolliculitis barbae, laser therapy for, 141–144
Pseudoporphyria cutanea tarda, drug-induced, dermatopathology of, 545–546
Psoriasiform drug eruptions, dermatopathology of, 553–554
Psoriasis, with HIV infection, 457–458
Pulsed-intense light sources, in hair removal, **373–385**
  equipment for, 377
  hair cycles and, 376–377
  multiple-treatment, 380–381
  PhotoDerm VI in, 381–384
    animal studies of, 382–383
    human studies of, 383–384
  single-treatment, 378–380
  technique for, 377–378
  variables in, 374–376
  vs. traditional methods, 373–374
Punch graft technique, in follicular unit transplantation, 277–278
Pustular drug eruptions, dermatopathology of, 542–543
$p21^{WAF1}$, as marker for malignant melanoma, 634–635
Pyloric atresia, epidermolysis bullosa with, 476

Q-switched lasers, in hair removal, 360
  in tattoo removal, 138–141

Radiation therapy, for basal cell carcinoma, 95–96
  for deep palmoplantar warts, 531
  for Merkel cell carcinoma, 100–101
  for microcystic adnexal carcinoma, 103
  for squamous cell carcinoma, 99
Rapid Fire Hair Implanter Carousel, in hair restoration, 294
5α-Reductase deficiency, and androgenetic alopecia, 248–249

5α-Reductase inhibitors, for androgenetic alopecia, 253–255
Reiter's syndrome, with HIV infection, 458
Respiratory failure, exfoliative diseases and, 73
Respiratory injuries, chemical warfare agents and, 45, 52
Retiform hemangioendothelioma, dermatopathology of, 513
Retinoids, for epidermodysplasia verruciformis, 528–529
Ruby lasers, in hair removal, 358, 412
  long-pulsed, in hair removal. See *Lasers.*
Rule of nines, in burn treatment, 63

S-100, in dermatopathology, 675
Sapphire lens, in epidermal cooling, in laser hair removal, 349
Scabies, with HIV infection, 454
Scalp reductions, follicular units in, 291
Scarring alopecia, immunopathology of, 566–567
Scars, hypertrophic, thermal burns and, 70–71
Schistosomiasis, military perspective on, 160–163
Sclerodermoid tissue reactions, drug-induced, dermatopathology of, 547–548
Sclerotic fibroma, of skin, histopathology of, 496–498
Sclerotic nevus, dermatopathology of, 617
Sebaceous carcinoma, military perspective on, 101–102
Seborrheic dermatitis, with HIV infection, 457
Sentinel lymphadenectomy, for malignant melanoma. See *Malignant melanoma.*
Sentinel node biopsies, for melanoma, 626–628
Separated needle stick and graft placement, in follicular unit transplantation, 299, 301, 304
Seromas, abdominal liposuction and, 833
Shaving, in hair removal, 373
Single strip harvesting, in hair restoration, 292–293
Sinusoidal hemangioma, dermatopathology of, 508
Skin biopsies, of epidermolysis bullosa, 479
Skin cancer, military perspective on, **93–111**
  atypical fibroxanthoma, 105
  basal cell carcinoma, 93–96
  dermatofibrosarcoma protuberans, 103–105
  desmoplastic melanoma, 106–108
  malignant fibrous histiocytoma, 105–106
  Merkel cell carcinoma, 99–101
  microcystic adnexal carcinoma, 102–103
  nevoid malignant melanoma, 108
  sebaceous carcinoma, 101–102
  squamous cell carcinoma, 96–99
  nonmelanoma. See *Nonmelanoma skin cancer.*
Skin erosions, abdominal liposuction and, 833
Skin substitutes, for thermal burns, 68
Skin-associated lymphoid tissue, lymphoma of, dermatopathology of, 580–583
Smallpox, military perspective on, 35–36
Sodium load, in liposuction, 758–759
Sodium stibogluconate, for leishmaniasis, 88–89
SoftLight System, in hair removal, 360–361, 410–413
Sparganosis, military perspective on, 163–164
Spindle-cell hemangioendothelioma, dermatopathology of, 511
Spindle-cell melanoma, dermatopathology of, 621–624
Spindle-cell nevus, dermatopathology of, 617
Sporotrichosis, military perspective on, 172–173
  with HIV infection, 456
Squamous cell carcinoma, military perspective on, 96–99
  with HIV infection, 463–464
Staphylococcal scalded skin syndrome, treatment of, in burn centers, 73
Starry-sky angiosarcoma, dermatopathology of, 517
Stevens-Johnson syndrome, dermatopathology of, 554
  with HIV infection, 462
Strawberry nevus, dermatopathology of, 507
Streptocerciasis, military perspective on, 155–156, 158–160
Strongyloidiasis, with HIV infection, 455
Subsurface imagery, lasers in, 145–147
Sulfur mustard. See *Chemical warfare agents.*
Synaptophysin, in dermatopathology, 677
Syphilis, with HIV infection, 453–454
Syringotropic cutaneous T-cell lymphoma, histology of, 610

T cells, melanoma antigen recognition by, 639
Tachycardia, epinephrine and, in liposuction, 754–755
Targetoid hemosiderotic hemangioma, dermatopathology of, 510
Tattoo removal, lasers in, 137–141
T-cell infiltrates, cutaneous. See *Cutaneous T-cell infiltrates.*
T-cell lymphomas. See *Cutaneous lymphomas.*
T-cell–rich B-cell lymphoma, morphology of, 598
Teledermatology, military perspective on, **113–124**
  Balkans peacekeeping operation, 120
  cost effectiveness, 121–122
  future directions, 122–123
  goals, 113–114
  historical aspects, 114–117
    analog signal telemedicine, 114
    digitalized videoteleconferencing, 114–116
    store and forward applications, 116–117
  National Naval Medical Center experience, 119–120
  Tripler Army Medical Center experience, 118
  Uniformed Services University of Health Sciences experience, 119–120
  Walter Reed Army Medical Center experience, 118–119
Telogen effluvium, planning for, in follicular unit transplantation, 285–286
Telomerase research, at Armed Forces Institute of Pathology, 130–132
Tetracycline, for autoimmune blistering diseases, 435
Textile-related contact dermatitis, diagnosis of, 707
Thighs, liposuction of, **849–863**
  complications of, 860
  postoperative care for, 860, 862
  postoperative ultrasound for, 862
  preoperative evaluation for, 851–854
  preoperative preparation for, 854
  technique for, 856–860
    aspiration, 857–860
    choice of, 860
    infusion of tumescent solution, 856–857
    marking, 854–856
Three-dimensional tumescent liposculpture, of abdomen, waist, and flanks, **805–813**
  areas to be treated, 805–806
  patient selection for, 806–807
  physical examination for, 807
  postoperative care for, 812–813
  preoperative preparation for, 807
  results of, 813
  technique for, 807–812
    anesthesia, 809
    instrumentation, 809
    marking, 807–809
    suctioning abdomen, 810
    suctioning waist, flanks, and fat pads, 810, 812

Tissue welding, lasers in, 144–145
Topical antibiotics, and contact dermatitis, 710
Topical glucocorticoids, and contact dermatitis, 710
Toxic epidermal necrolysis, dermatopathology of, 554
  treatment of, in burn centers, 72–74
  with HIV infection, 462
Tranilast, for autoimmune blistering diseases, 435
Transforming growth factor-β, as marker for malignant melanoma, 640
Transplantation, follicular unit. See *Follicular unit transplantation.*
Trench foot, and military readiness, 9–11
Triamcinolone, for thermal burns, 71
  in liposuction, 756–757
Trichloroacetic acid, for condylomata acuminata, 524
Trimethoprim-sulfamethoxazole, hypersensitivity to, in HIV-infected patients, 461–462
Tropical immersion foot, and military readiness, 11–12
Tumescent liposculpture, three-dimensional. See *Three-dimensional tumescent liposculpture.*
Tumescent solutions, in liposuction, **751–759**
    and fluid homeostasis, 757
    avoidance of postoperative sedatives, 753
    bupivacaine in, 756
    chloride load in, 758
    dosage in milligrams, 752
    knowledge of correct dosage, 752
    lactated Ringer's solution in, 757–758
    lidocaine solution, 752
    lidocaine/epinephrine concentrations in, 753–756
    maximum safe dosage of, 751
    normal saline as solvent, 753, 757
    preparation of, at time of surgery, 752
      by licensed personnel, 752
    record-keeping in, 753
    saving empty bottles, 752–753
    shared responsibility for, 753
    shelf life of, 756
    signed written orders for, 751–752
    sodium load in, 758–759
    triamcinolone in, 756–757
  in ultrasonic assisted liposuction, 767
Tungiasis, military perspective on, 179–180
Tweezing, in hair removal, 373

Ulcers, in HIV-infected patients, foscarnet and, 462
Ulex europaeus agglutinin, in dermatopathology, 673
Ultrasonic assisted liposuction, **761–771**
  biologic effects of, 763–766
  complications of, 769
  fat aspirate from, histology of, 766
  historical aspects of, 761–762
  indications for, 766–767
  instrumentation for, 768–769
  physics of, 762–763
  postoperative, 769–770
    of thighs, 862
  preoperative evaluation for, 767
  safety of, 769
  technique for, 767–768
  tumescent solution in, 767
Ultraviolet radiation exposure, and military readiness, 3
Umbilical hernia, and abdominal liposuction, 829
Urticaria, with HIV infection, 461

Vaccinia, military perspective on, 37
Vandillylate neuropeptide inhibitors, for cutaneous injuries, due to chemical warfare agents, 52
Varicella, differential diagnosis of, 37–38
  with HIV infection, 448
Vascular endothelial growth factor, as marker for malignant melanoma, 638–639
Vasculitis, drug-induced, dermatopathology of, 550–551
Verruca plana, dermatopathology of, 532–533
Verruca vulgaris, dermatopathology of, 525–527
Verrucous hemangioma, dermatopathology of, 508
Verrucous melanoma, dermatopathology of, 624
Vimentin, in dermatopathology, 668
Viral infections, exotic. See *Exotic viral infections.*
  with HIV infection. See *HIV infection.*

Waist, three-dimensional tumescent liposculpture of. See *Three-dimensional tumescent liposculpture.*
Warm water immersion foot, and military readiness, 11–12
Warts, palmoplantar, dermatopathology of, 530–531
Waxing, in hair removal, 373
Wringer-Kolopp disease, histology of, 610–611
Wound decontamination, lasers in, 136–137

Xenografts, for thermal burns, 67–68
Xerotic dermatitis, with HIV infection, 460–461

Zidovudine, hypersensitivity to, in HIV-infected patients, 462
Zinc, for cutaneous injuries, due to chemical warfare agents, 53
Zinc oxide, for diaper dermatitis, 238
Zygomycosis, military perspective on, 177–179